Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

Bright light therapy, a standard treatment for seasonal depression, may also help people who experience depression year-round ...

Acupuncture. Ketamine infusions. "Electroshock" or electroconvulsive therapy. The existing treatment options for those ...

A recent study published in the Journal of Affective Disorders suggests that a single dose of psilocybin may offer hope for U ...

The criteria for diagnosing SAD are similar to diagnosing major ... disorders. On average, SAD will last about five months of ...

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

Participants who responded to the treatment showed a significant decline in HAMD-17 scores ... In this study, we explored the potential effects of electroconvulsive therapy on inflammatory markers in ...